Chronic Myeloid Leukemia: Current Application of Cytogenetics and Molecular Testing for Diagnosis and Treatment
Chronic myeloid leukemia provides an illustrative disease model for both molecular pathogenesis of cancer and rational drug therapy. Chronic myeloid leukemia is a clonal stem cell disease caused by an acquired somatic mutation that fuses, through chromosomal translocation, the abl and bcr genes on
Chronic Myeloid Leukemia: Diagnosis and Treatment
Chronic myeloid leukemia (CML) has become a model in research and management among malignant disorders. Since the discovery of the presence of a unique and constant chromosomal abnormality slightly more than 40 years ago, substantial progress has been made in the understanding of the biology of the
Lung Abnormalities after Dasatinib Treatment for Chronic Myeloid Leukemia: A Case Series
Tyrosine kinase inhibitors have revolutionized the treatment of chronic myeloid leukemia and are increasingly used for other indications. Fluid retention, however, including pleural effusions, are a significant side effect of imatinib, the first-line treatment for chronic myeloid leukemia. We
Denaturing-HPLC-Based Assay for Detection of ABL Mutations in Chronic Myeloid Leukemia Patients Resistant to Imatinib
Background: Despite the efficacy of the BCR-ABL tyrosine kinase inhibitor Imatinib mesylate for the treatment of chronic myeloid leukemia (CML), resistance has been observed in a proportion of cases, especially those with advanced stages of the disease. Point mutations within the ABL kinase domain
Video and Photo: Tasigna Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies.
- Tasigna produced responses in 40% of patients with Philadelphia chromosome-positive chronic myeloid leukemia resistant or intolerant to prior treatment - Approval and availability in US means Novartis can offer physicians and patients a comprehensive treatment approach for this disease EAST
Double-Gradient-Denaturing-Gradient Gel Electrophoresis for Mutation Screening of the BCR-ABL Tyrosine Kinase Domain in Chronic Myeloid Leukemia Patients
Chronic myeloid leukemia (CML) is a rare hematopoietic stem cell disorder characterized by the t(9;22) translocation. This somatic event leads to the formation of the BCR-ABL fusion gene, which is translated in a functional protein (1). The Bcr-Abl oncoprotein differs from the endogenous c-Abl
Pathologic quiz case: Cauda Equina Syndrome in a 65-year-old man, status post-bone marrow transplant for chronic myeloid leukemia
A 65-year-old man with a history of chronic myeloid leukemia (CML) presented with fatigue, a 9-kg weight loss, and increasing low back and buttock pain. He had received an allogeneic stem cell transplant 11 months previously. His medications on admission included cyclosporine and prednisone. On
Chronic Myeloid Leukemia - Gleevec resistance is opening a market for synergistic use.
M2 PRESSWIRE-18 February 2003-Research and Markets: Chronic Myeloid Leukemia - Gleevec resistance is opening a market for synergistic use(C)1994-2003 M2 COMMUNICATIONS LTD RDATE:02152003 With CML`s relatively low prevalence, the potential market for drugs launched for this indication historically
Cauda equina syndrome in a 65-year-old man, status post-bone marrow transplant for chronic myeloid leukemia. .
A 65-year-old man with a history of chronic myeloid leukemia (CML) presented with fatigue, a 9-kg weight loss, and increasing low back and buttock pain. He had received an allogeneic stem cell transplant 11 months previously. His medications on admission included cyclosporine and prednisone. On
Panel endorses dasatinib for imatinib-resistant CML.
ATLANTA - Based on input from an expert advisory panel, the oral tyrosine kinase inhibitor dasatinib may be approved by the Food and Drug Administration for the treatment of imatinib-resistant or -intolerant adults with chronic myeloid leukemia. Other potential indications include treatment of
